Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 586-594

  Bubalo, Joseph S ^a   Cherala, Ganesh ^b   McCune, Jeannine S ^c   Munar, Myrna Y ^b   Tse, Sunny ^d   Maziarz, Richard ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

aprepitant; azole antifungals; cyclophosphamide; CYP450; Hematopoietic cell transplant; myeloablative regimen; pharmacokinetics; sinusoidal obstruction syndrome

Indexed keywords

APREPITANT; BUSULFAN; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; VOMITING; YOUNG ADULT;

EID: 84859059106     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011398243     Document Type: Article

References (27)

1. Winn RJ, McClure JS. NCNN Clinical Practice Guidelines in Oncology (NCNN Guidelines™). Clinical Information & Publications; Rockledge, PA: National Comprehensive Cancer Network; 2003.
2. Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant. 2008;42:501-606.
3. Chan KW, Mullen CA, Worth LL, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002;29:963-965. (Pubitemid 34845950)
4. Lindley C, Hamilton G, McCune JS, et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002;30:814-822. (Pubitemid 34671094)
5. Aprepitant (Emend) [package insert]. Whitehouse Station, NJ: Merck; 2006.
6. Chang TK, Weber GF, Crespi WL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993;53:5629-5637. (Pubitemid 23360263)
7. Chang TK, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9- ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997;7:211-221. (Pubitemid 27290635)
8. Griskevicius L, Yasar U, Sandberg M, et al. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol. 2003;59:103-109. (Pubitemid 36793721)
9. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol. 2000;59: 961-972. (Pubitemid 30110812)
10. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res. 1997;57:4229-4235. (Pubitemid 27413430)
11. Roy P, Yu LJ, Crespi CL, Waxman DJ Development of asubstrate- activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999;27:655-666. (Pubitemid 29252439)
12. Xie HJ, Yasar Y, Lundgren S, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003;3:53-61.
13. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135-1164.
14. Baumann F, Preiss R. Cyclophosphamide and related anticancer drugs. J Chromatogr B Biomed Sci Appl. 2001;764:173-192. (Pubitemid 33044665)
15. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007;13:853-862. (Pubitemid 46902444)
16. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101:2043-2048. (Pubitemid 36237612)
17. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39:155-165.
18. Constanzer ML, Chavez-Eng CM, Dru J, et al. Determination of anovel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;807:243-250. (Pubitemid 38759989)
19. Kalhorn TF, Howald WN, Cole S, et al. Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography- mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835:105-113.
20. Bergstrom M, Hargreaves RJ, Burns HD, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004;55:1007-1012. (Pubitemid 38581916)
21. Bubalo JS, Curtin PT, Maziarz RT, et al. A double blinded pilot study of aprepitant vs placebo combined with standard antiemetics for the control of nausea and vomiting during hematopoietic cell transplantation. ASCO Annual Meeting Proceedings. 2007;25 (suppl 18, pt 1):abstract 9112.
22. Massaro AM, Lenz KL. Aprepitant: anovel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39:77-85. (Pubitemid 40052382)
23. Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added toa standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol. 2007;59: 407-412. (Pubitemid 46025528)
24. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 isthe major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004;32:1287-1292. (Pubitemid 39410914)
25. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730-1744. (Pubitemid 44885328)
26. de Jonge ME, Huitema AD, Holtkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005;56:370-378. (Pubitemid 41095400)
27. Rae JM, Souknova NV, Flockhart DA, Desta Z. Triethylenethiophosphoramide is aspecific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos. 2002;30:525-530. (Pubitemid 34456973)